# A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)

> **NCT00439803** · PHASE1 · COMPLETED · sponsor: **AlphaVax, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **BIOLOGICAL:** AVX601
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** AVX601
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** AVX601
- **BIOLOGICAL:** AVX601
- **BIOLOGICAL:** AVX601
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00439803
- **Lead sponsor:** AlphaVax, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2008-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00439803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00439803, "A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00439803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*